tbuckley/cabot-search huggingface dataset:
Abstract 13116: The Association Between Depression and Mortality and Amputation Outcomes in Patients With Peripheral Artery Disease: A Systematic Review and Meta-Analysis
Authors: Lindsey E Scierka, Zain V Ahmed, Sameh Yousef, AHMAD ARHAM, Alyssa A Grimshaw, Kristie Harris, Matthew Burg, Carlos Mena-hurtado, Kim G Smolderen
Journal: Circulation (2021)

Introduction: Peripheral artery disease (PAD) is associated with significant morbidity and mortality. Part of its management requires optimizing adherence to medications and lifestyle changes. Depression may negative affect this goal and has been identified as a potential risk factor for PAD incidence and progression. To better understand this risk, we conducted a systematic review and meta-analysis to summarize the strength of the association between depression and mortality and amputation in patients with PAD. Hypothesis: Comorbid depression is associated with an increased risk of mortality and amputation risk in patients with PAD. Methods: We performed a systematic search of Cochrane Library, Embase, Google Scholar, Medline, Pubmed, PsychInfo, Scopus, and Web of Science Core Collection databases for studies that report the comorbidity of depression or depressive symptoms in patients with PAD. Databases were searched on December 16 th , 2020. Risk of bias was assessed used Cochrane ROBINS-I. Funnel plot and Egger’s regression asymmetry test were used to assess publication bias. A random effects model was used to estimate the combined overall effect as odds ratio (OR) or hazard ratios (HR). Results: In the 6 studies included (n= 274,442 patients with PAD), 36,134 patients (13.2%) had comorbid depression. Depression was associated with an increased risk of mortality (HR 1.37, 95% CI 1.1-1.70, p-value: 0.003) and amputation (HR 1.21, 95% CI 1.02-1.45, p-value: 0.031). Risk of bias was moderate for all studies and Egger’s test was not statistically significant (p-value: 0.127 for mortality, 0.867 for amputation). Conclusion: There is a 21% increased risk of amputation and 37% increase in risk of mortality in PAD patients with comorbid depression. Future work will need to study explanatory mechanisms and directionality of the association, while clinical implications include realizing integrated care to address the depression burden in patients with PAD.
Abstract 13911: Regulation of STAT3 Phosphorylation Through βIV-Spectrin Interaction and Its Role in Concentric versus Eccentric Hypertrophy
Authors: Drew Nassal, Shivangi Mohta, Nehal Patel, Xianyao Xu, Mei Han, Peter J Mohler, Thomas J Hund
Journal: Circulation (2021)

Hypertrophic growth is a critical determinant of cardiac function in the development of heart failure. In pressure overload, hypertrophy is divided by early adaptive remodeling defined by concentri...
BMSC-derived extracellular matrix better optimizes the microenvironment to support nerve regeneration
Authors: Shengran Wang, Changlai Zhu, Bin Zhang, Junxia Hu, Jinghui Xu, Chengbin Xue, Shuangxi Bao, Xiaokun Gu, Fei Ding, Yumin Yang, Xiaosong Gu, Yun Gu
Journal: Biomaterials (2021)

A favorable microenvironment plays an important role in nerve regeneration. Extracellular matrix (ECM) derived from cultured cells or natural tissues can facilitate nerve regeneration in the presence of various microenvironmental cues, including biochemical, spatial, and biomechanical factors. This study, through proteomics and three-dimensional image analysis, determines that the components and spatial organization of the ECM secreted by bone marrow mesenchymal cells (BMSCs) are more similar to acellular nerves than those of the ECMs derived from Schwann cells (SCs), skin-derived precursor Schwann cells (SKP–SCs), or fibroblasts (FBs). ECM-modified nerve grafts (ECM-NGs) are engineered by co-cultivating BMSCs, SCs, FBs, SKP-SCs with well-designed nerve grafts used to bridge nerve defects. BMSC-ECM-NGs exhibit the most promising nerve repair properties based on the histology, neurophysiology, and behavioral analyses. The regeneration microenvironment formed by the ECM-NGs is also characterized by proteomics, and the advantages of BMSC-ECM-NGs are evidenced by the enhanced expression of factors related to neural regeneration and reduced immune response. Together, these findings indicate that BMSC-derived ECMs create a more superior microenvironment for nerve regeneration than that by the other ECMs and may, therefore, represent a potential alternative for the clinical repair of peripheral nerve defects.
Abstract PR-011: Loss of compensatory feedback mechanism involving splicing factor SRSF1 accelerates <i>KrasG12D</i>-mediated pancreatic cancer initiation
Authors: Ledong Wan, Kuan-Ting Lin, Mohammad A. Rahman, Zhikai Wang, Youngkyu Park, David A. Tuveson, Adrian R. Krainer
Journal: Cancer Research (2021)

Abstract KRAS is recurrently mutated in pancreatic ductal adenocarcinoma (PDAC), triggering the formation of acinar-to-ductal metaplasia (ADM) and pancreatic intraepithelial neoplasia (PanIN). However, the majority of pancreatic cells from KC (LSL-KrasG12D/+; Pdx-1-Cre) mice carrying the KrasG12D mutation remain morphologically normal for a long time, suggesting the existence of compensatory feedback mechanisms that buffer KrasG12D signaling, and that additional steps are required for disrupting cell homeostasis and promoting transformation. Here we found that splicing factor SRSF1, which is associated with cell transformation, is downregulated in the majority of morphologically normal pancreas cells with the KrasG12D mutation as a compensatory feedback mechanism. To assess the role of SRSF1 in PDAC, we generated a transgenic mouse strain (SC) with Dox-inducible pancreatic-specific expression of SRSF1 protein. Elevated SRSF1 alone is sufficient to induce pancreatitis and ADM transformation. By further crossing the SC strain with KrasG12D alone (KSC) or together with Trp53R172H (KPSC), we found that increasing SRSF1 accelerated KrasG12D-mediated tumor initiation and resulted in more aggressive PDAC. To address the underlying mechanisms of SRSF1’s involvement in the homeostatic response to KrasG12D mutation and in PDAC initiation, we generated organoid lines from the above mouse strains. Following Dox induction, elevated SRSF1 with Kras WT or KrasG12D consistently activated MAPK signaling, which is one of the top negatively enriched pathways in response to KrasG12D. Furthermore, SRSF1 promoted the expression of Il1r1—an IL1 receptor associated with the activation of MAPK signaling—by regulating an alternative-splicing event in the 5’UTR to generate a more stable mRNA isoform. We conclude that decreased SRSF1 is a compensatory feedback mechanism in pancreatic cells against the KrasG12D mutation, whose disruption facilitates PDAC initiation. Citation Format: Ledong Wan, Kuan-Ting Lin, Mohammad A. Rahman, Zhikai Wang, Youngkyu Park, David A. Tuveson, Adrian R. Krainer. Loss of compensatory feedback mechanism involving splicing factor SRSF1 accelerates KrasG12D-mediated pancreatic cancer initiation [abstract]. In: Proceedings of the AACR Virtual Special Conference on Pancreatic Cancer; 2021 Sep 29-30. Philadelphia (PA): AACR; Cancer Res 2021;81(22 Suppl):Abstract nr PR-011.
Oral Administration of Mavorixafor, a CXCR4 Antagonist, Increases Peripheral White Blood Cell Counts across Different Disease States
Authors: David C. Dale, Steven P. Treon, David F. McDermott, Diego Cadavid, Xia Luo, Varun Garg, Weihua Tang, Honghua Jiang, Kelly Chen, Arthur G. Taveras, Ashish Bhandari, Jean Donadieu
Journal: Blood (2021)
Immunogenicity and safety of the human papillomavirus vaccine in young survivors of cancer in the USA: a single-arm, open-label, phase 2, non-inferiority trial
Authors: Wendy Landier, Smita Bhatia, F Lennie Wong, Jocelyn M York, Jessica S Flynn, Harrison M Henneberg, Purnima Singh, Kandice Adams, Karen Wasilewski-Masker, Brooke Cherven, Rama Jasty-Rao, Marcia Leonard, James A Connelly, Saro H Armenian, Leslie L Robison, Anna R Giuliano, Melissa M Hudson, James L Klosky
Journal: The Lancet Child & Adolescent Health (2021)
A Phase I/II Dose-Escalation Multi-Center Study to Evaluate the Safety of Infusion of Natural Killer Cells or Memory T Cells As Adoptive Therapy in Coronavirus Pneumonia and/or Lymphopenia: (RELEASE NCT04578210)
Authors: Antonio Pérez-Martínez, Alejandro Martín-Quirós, Cristina Ferreras, Karima Al-Akioui, Marta Mora-Rillo, Rosa Goterris, María Luisa Briones, Mercedes Gasior, Paula Amat, Raquel de Paz, Pilar Guerra-García, Javier Queiruga-Parada, Merche Bou, Carmen Mestre-Durán, Alberto Borobia, Antonio J Carcas, Jose Luis Vicario, Miguel Ángel Moreno, Dolores Planelles, Antonio Balas, Cristina Eguizábal, Bernat Soria, Carlos Solano
Journal: Blood (2021)
The COVID-19 pandemic is intricately linked to biodiversity loss and ecosystem health
Authors: Odette K Lawler, Hannah L Allan, Peter W J Baxter, Romi Castagnino, Marina Corella Tor, Leah E Dann, Joshua Hungerford, Dibesh Karmacharya, Thomas J Lloyd, María José López-Jara, Gloeta N Massie, Junior Novera, Andrew M Rogers, Salit Kark
Journal: The Lancet Planetary Health (2021)

The ongoing COVID-19 pandemic, caused by zoonotic SARS-CoV-2, has important links to biodiversity loss and ecosystem health. These links range from anthropogenic activities driving zoonotic disease emergence and extend to the pandemic affecting biodiversity conservation, environmental policy, ecosystem services, and multiple conservation facets. Crucially, such effects can exacerbate the initial drivers, resulting in feedback loops that are likely to promote future zoonotic disease outbreaks. We explore these feedback loops and relationships, highlighting known and potential zoonotic disease emergence drivers (eg, land-use change, intensive livestock production, wildlife trade, and climate change), and discuss direct and indirect effects of the ongoing pandemic on biodiversity loss and ecosystem health. We stress that responses to COVID-19 must include actions aimed at safeguarding biodiversity and ecosystems, in order to avoid future emergence of zoonoses and prevent their wide-ranging effects on human health, economies, and society. Such responses would benefit from adopting a One Health approach, enhancing cross-sector, transboundary communication, as well as from collaboration among multiple actors, promoting planetary and human health.
Abstract 14945: Association of Cardiac Rehabilitation With Decreased Hospitalizations and Mortality After Cardiac Valve Surgery
Authors: Devin K Patel, Meredith S Duncan, Brian R Lindman, Ashish S Shah, Mary A Whooley, Robert A Greevy, Matthew S Freiberg, Justin M Bachmann
Journal: Circulation (2018)

Introduction: Cardiac rehabilitation (CR) is indicated for patients undergoing cardiac valve surgery (CVS), but CR utilization and its association with outcomes have not been well-described after C...
Abstract 8911: Incidence and Risk Factors of Aortic Arch Obstruction After the Comprehensive Stage II Procedure
Authors: Annaka Gilmore, Jo Ann Davis, Samantha Low, Joanne Chisolm, John Kelly, Emily Hone, Sasha Bai, Patrick I McConnell, Mark E Galantowicz, Clifford L Cua
Journal: Circulation (2021)

Introduction: Minimal data exist about the incidence and risk factors for arch intervention after Comprehensive Stage II (CSII). Goal of this study was to document incidence of arch interventions after CSII and determine if any differences existed between those that underwent an arch intervention (aiCSII) versus those did not have an intervention. Methods: Retrospective chart review of all hypoplastic left heart syndrome patients that underwent a CSII between 6/1/2005 through 2/1/2020 was performed. Univariate analysis was conducted in addition to principal components analysis (PCA). Results: One hundred patients were evaluated. Sixteen patients underwent 24 arch interventions. Age at initial arch reintervention was 1.3 + 1.2 years (median 1.0 years, range 0.5 - 2.2 years). Univariate analysis showed that the aiCSII group were more likely to be female, to have had a retrograde arch intervention post-hybrid procedure, and to be younger at time of CSII. On echocardiograms, aiCSII group had significantly higher pre-CSII patent ductus arteriosus velocities, arch velocities on their 1 st post-operative and discharge study post-CSII, and arch velocities pre-Fontan. Gradients were higher in the aiCSII via pre-Fontan catheterization. With PCA, echocardiographic and catheterization data remained significantly associated with aiCSII versus those that did not undergo an arch intervention (OR = 4.5 (1.9, 19.8), p &lt; 0.01). Mortality was not associated with arch intervention. Conclusions: Incidence of arch intervention post-CSII was 16%. Echocardiographic arch gradients during the CSII hospitalization were the strongest predictors for subsequent aortic arch interventions. Further studies are needed to determine any modifiable variables that may reduce the incidence of arch interventions.
Entospletinib (ENTO) and Decitabine (DEC) Combination Therapy in Older Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Patients with Mutant TP53 or Complex Karyotype Is Associated with Poor Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial
Authors: Vu H. Duong, Amy S. Ruppert, Alice S. Mims, Uma Borate, Eytan M. Stein, Maria R. Baer, Wendy Stock, Tibor Kovacsovics, William G. Blum, Martha L. Arellano, Gary J. Schiller, Rebecca L. Olin, James M. Foran, Mark R. Litzow, Tara L. Lin, Prapti A. Patel, Matthew C. Foster, Robert L. Redner, Zeina Al-Mansour, Christopher R. Cogle, Ronan T. Swords, Robert H. Collins, Jo-Anne Vergilio, Nyla A. Heerema, Leonard Rosenberg, Ashley O. Yocum, Sonja Marcus, Timothy Chen, Franchesca Druggan, Mona Stefanos, Theophilus J Gana, Abigail B. Shoben, Brian J. Druker, Amy Burd, John C. Byrd, Ross L. Levine, Michael M. Boyiadzis
Journal: Blood (2021)
Molecular Signatures of Immune Pressure and Immune Escape in Hematological Malignancies
Authors: Simona Pagliuca, Carmelo Gurnari, Tariq Kewan, Waled Bahaj, Minako Mori, Laila Terkawi, Christopher Haddad, Ishani Nautiyal, Valeria Visconte, Jaroslaw P. Maciejewski
Journal: Blood (2021)
Targeting EZH1/2 to Restore Chemosensitivity in Dormant Myeloid Leukemia Stem Cells
Authors: Kyung Hee Chang, Mahesh Basyal, Zoe Alaniz, Daisuke Honma, Shinji Tsutsumi, Cedric E. Dos Santos, Naval Daver, Michael Andreeff
Journal: Blood (2021)
포스터전시 : 자가 면역성 간염에서 간경화로 진행된 환자에서 동반된 전신성 경화증 1예 (초)
Authors: 유병철, 정승원, 강은정, 이세환, 김상균, 장재영, 천영국, 김영석, 조영덕, 김홍수, 김부성
Journal: Clinical and Molecular Hepatology (2010)
A Prospective Phase 2 Study Testing High Dose Post-Transplant Cyclophosphamide As Sole Ghvd Prophylaxis after Matched Allotransplant Using Baltimore-Based Reduced-Intensity Conditioning Regimens and PBSC As Source of Graft
Authors: Patrice Chevallier, Amandine Le Bourgeois, Alice Garnier, Pierre Peterlin, Yannick Le Bris, Marion Eveillard, Béatrice Mahé, Viviane Dubruille, Nicolas Blin, Anne Lok, Cyrille Touzeau, Thomas Gastinne, Benoit Tessoulin, Maxime Jullien, Sophie Vantyghem, Philippe Moreau, Steven Le Gouill, Marie C Bene, Thierry Guillaume
Journal: Blood (2021)
A New Role for the SRC Family Member HCK As a Driver of BCR/SYK Signaling in MYD88 Mutated Lymphomas
Authors: Manit Munshi, Xia Liu, Amanda Kofides, Nickolas Tsakmaklis, Maria G Demos, Maria Luisa Guerrera, Zachary R Hunter, M. Lia Palomba, Kimon V. Argyropoulos, Christopher J Patterson, Kirsten Meid, Joshua Gustine, Jorge J. Castillo, Shayna Sarosiek, Catherine A Flynn, Jinhua Wang, Sara J Buhrlage, Nathanael S Gray, Nikhil C. Munshi, Kenneth C. Anderson, Guang Yang, Steven P Treon
Journal: Blood (2021)
Abstract 9505: Myocardial Energetic Impairment is the Basis for Reduced Cardiac Reserve and Exercise-Induced Pulmonary Congestion in Heart Failure With Preserved Ejection Fraction: Insights From Novel Cardiopulmonary Magnetic Resonance Imaging
Authors: Matthew K Burrage, Moritz Hundertmark, Ladislav Valkovic, William D Watson, Jennifer Rayner, Nikant Sabharwal, Vanessa Ferreira, Stefan Neubauer, Jack J Miller, Andrew J Lewis, Oliver J Rider
Journal: Circulation (2021)

Introduction: Abnormal cardiac mitochondrial function and energetics may be a unifying feature in the pathogenesis of heart failure with preserved ejection fraction (HFpEF), while transient pulmonary congestion during exercise is an important determinant of reduced exercise capacity and symptoms. Hypothesis: We hypothesized that a gradient of myocardial energetic impairment exists across the spectrum of HFpEF and limits cardiac reserve during exercise, leading to transient pulmonary congestion. Methods: 43 patients across the spectrum of diastolic dysfunction and HFpEF (age-matched controls n=11; type 2 diabetes (T2DM) n=9; HFpEF n=14; severe diastolic dysfunction due to cardiac amyloid n=9) underwent assessment of cardiac energetics (myocardial phosphocreatine to ATP ratio, PCr/ATP) and function using CMR, and lung water using a novel MR proton density mapping sequence. Studies were performed at rest and during exercise (20 W for 6 minutes). Results: Paralleling the stepwise decline in diastolic function across the groups (E/e’ ratio p&lt;0.001) was an increase in NT-pro BNP (p&lt;0.001) and a reduction in PCr/ATP (p&lt;0.001). During exercise, lower left ventricular (LV) diastolic filling rates (r 0.58, p&lt;0.001), left atrial (LA) dilatation (r -0.52, p&lt;0.001), lower right ventricular (RV) contractile reserve (ΔRVEF; r 0.57, p&lt;0.001), and right atrial (RA) dilatation (r -0.71, p&lt;0.001) were strongly linked with impaired energetics. The pulmonary proton density sequence provided images that scaled linearly with water content, validated using a water-doped sponge phantom (r 0.98, p&lt;0.0001), and revealed transient pulmonary congestion in patients with HFpEF (+4.4% [0.5, 6.4], p=0.002) and amyloid (+6.4% [3.3, 10.0], p=0.004), which was not seen in controls (-0.1% [-1.9, 2.1], p=0.89) or T2DM (+0.8% [-1.7, 1.9], p=0.82). Exercise-induced pulmonary congestion was associated with reduced LV diastolic filling (r -0.33, p=0.03), RVEF augmentation (r-0.50, p&lt;0.001), RA dilatation (r 0.44, p=0.004), and impaired myocardial energetics (r -0.43, p=0.004). Conclusion: A gradient of myocardial energetic deficit exists across the spectrum of HFpEF, leading to impaired cardiac functional reserve and transient exercise-induced pulmonary congestion.
Photosynthetic Oxygenation‐Augmented Sonodynamic Nanotherapy of Hypoxic Tumors
Authors: Shuting Lu, Wei Feng, Caihong Dong, Xinran Song, Xiang Gao, Jinhe Guo, Yu Chen, Zhongqian Hu
Journal: Advanced Healthcare Materials (2021)

Reactive oxygen species (ROS) has been employed as a powerful therapeutic agent for eradicating tumor via oxidative stress. As an emerging ROS-involving noninvasive anticancer therapeutic modality, sonodynamic therapy (SDT) with high tissue penetration depth and benign remote spatiotemporal selectivity has been progressively utilized as the distinct alternative for ROS-based tumor treatment. However, the hypoxic tumor microenvironment substantially restricts the sonodynamic effect. In this work, an oxygen self-sufficient hybrid sonosensitizer on the basis of photosynthetic microorganisms cyanobacteria (Cyan) integrated with ultrasmall oxygen-deficient bimetallic oxide Mn1.4 WOx nanosonosensitizers, termed as M@C, is designed and engineered to overcome the critical issue of hypoxia-induced tumor resistance and strengthen the SDT effect. The sustained photosynthetic oxygen production by Cyan under light illumination can promote Mn1.4 WOx nanosonosensitizers to produce more ROS against cancer cells both in vitro and in vivo under ultrasound (US) irradiation. Especially, the sustained oxygen evolution for suppressing the gene expression of hypoxia-inducible factor 1alpha (HIF-1α) further boosts and augments the SDT efficiency. Thus, this work provides the paradigm that the rationally engineered biohybrid microorganism-based multifunctional sonosensitizers can serve as an effective bioplatform for augmenting the therapeutic efficiency of SDT, particularly for the treatment of hypoxic tumors.
COVID-19 Among Patients with Hematological Malignancies: Experience from a Tertiary Center Showing Lower Than Expected Mortality and Establishing the Safety of in-Hospital Patient Care during the Pandemic
Authors: Shlomzion Aumann, Uria Tsubary, Sarah Israel, Dina Ben Yehuda, David Lavie, Neta Goldschmidt, Vladimir Vainstein, Diana Libster, Revital Saban, Adir Shaulov, Batia Avni, Boaz Nachmias, Sigal Grisariu, Ora Paltiel, Moshe Gatt, Eran Zimran
Journal: Blood (2021)
Platelet Transfusions Can Increase or Decrease the Inflammatory Response and Mortality in a Murine Model of Neonatal Polymicrobial Sepsis
Authors: Patricia E Davenport, Hsuan-Hao Fan, Emily Nolton, Henry Feldman, Viola Lorenz, Jorge Canas, Maikel Acosta-Zaldivar, William Yakah, Sean R Stowell, Julia Koehler, Camilia Martin, Donald E Mager, Martha Sola-Visner
Journal: Blood (2021)
Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia
Authors: Matthew S. Davids, Danielle M. Brander, Svitlana Tyekucheva, Chinheng Chen, James Kaminski, Josie Montegaard, Alvaro J. Alencar, Leyla Shune, Mohammad Omaira, Caron Jacobson, Philippe Armand, Samuel Y. Ng, Jennifer L. Crombie, Ann S. LaCasce, Jon E. Arnason, Ephraim Hochberg, Ronald W. Takvorian, Jeremy S. Abramson, David C. Fisher, Jennifer R Brown
Journal: Blood (2021)
Patterns of Salvage Therapy in Patients with Acute Myeloid Leukemia Treated Upfront with Azacitidine or Decitabine: Results from the Pethema AML Registry
Authors: Jorge Labrador, Adolfo de la Fuente, David Martínez-Cuadrón, Rebeca Rodríguez-Veiga, Josefina Serrano, Mar Tormo, Jose Pérez-Simón, Fernando Ramos, Teresa Bernal del Castillo, Maria López-Pavía, Fernanda Trigo, Pilar Martinez Sanchez, Juan Ignacio Rodriguez-Gutierrez, Carlos Rodriguez, Cristina Gil, Daniel Garcia, Susana Vives, Maria Angeles Foncillas, Manuel Perez Encinas, Andrés Novo, Isabel Recio, Gabriela Rodriguez Macias, Juan Miguel Bergua Burgues, Victor Noriega Concepcion, Esperanza Lavilla, Alicia Roldán Pérez, Miguel A. Sanz, Pau Montesinos
Journal: Blood (2021)